Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 243 results found since Jan 2013.
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Nanobodies Neutralizing Lassa Virus
Lassa Hemorrhagic Fever (LHF) is a serious disease caused by infection with Lassa virus (LASV) – highly prevalent in West Africa and spreading globally. LASV is associated with high morbidity and mortality rates, annually infecting 100,000 to 300,000 individuals and causing 5,000 deaths. Developing prophylactics and treatment for LASV is difficult due to challenges in inducing neutralizing antibodies and producing their target, the LASV glycoprotein trimer (GPC). LASV poses a severe public health threat with infections expanding outside the traditional endemic areas and no LHF- specific vaccines or therapies.Researchers ...
Source: NIH OTT Licensing Opportunities - May 10, 2022 Category: Research Authors: ott8admin Source Type: research
Novel COVID-19 Vaccine for Patients With Blood Cancers Novel COVID-19 Vaccine for Patients With Blood Cancers
A novel vaccine (CoVac-1) currently in clinical trials in Germany induced T-cell immune responses in a large proportion of patients with blood cancers and B cell deficiencies.Medscape Medical News
Source: Medscape Allergy Headlines - April 19, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Defining the risk of SARS-CoV-2 variants on immune protection
We report the development of reagents, methodologies, models, and pivotal findings facilitated by this collaborative approach and identify future challenges. This program serves as a template for the response against rapidly evolving pandemic pathogens by monitoring viral evolution in the human population to identify variants that could erode the effectiveness of countermeasures.PMID:35361968 | DOI:10.1038/s41586-022-04690-5
Source: Cancer Control - April 1, 2022 Category: Cancer & Oncology Authors: Marciela M DeGrace Elodie Ghedin Matthew B Frieman Florian Krammer Alba Grifoni Arghavan Alisoltani Galit Alter Rama R Amara Ralph S Baric Dan H Barouch Jesse D Bloom Louis-Marie Bloyet Gaston Bonenfant Adrianus C M Boon Eli A Boritz Debbie L Bratt Traci Source Type: research
What to Know About a Fourth COVID-19 Vaccine Dose
Most people ages 12 and older are considered “up to date” with their COVID-19 vaccines if they received either three doses of the mRNA shots from Pfizer-BioNTech or Moderna, or two doses of Johnson & Johnson’s Janssen vaccine. But some public health experts say another dose might be needed in the coming months.
The Washington Post reports today that Pfizer and BioNTech soon plan to request authorization from the U.S. Food and Drug Administration (FDA) for a fourth dose of their vaccine in people ages 65 and older. In the past few days, Albert Bourla, Pfizer’s CEO, has said that he believes every...
Source: TIME: Health - March 15, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
NIDCR's Spring 2022 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Spring 2022 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NIDCR News
Science Advances
NIDCR News
NIH & NIDCR Release “Oral Health in America: Advances and Challenges”
In December, NIDCR announced the release of a report that provides a comprehensive snapshot of oral health in America, detailing 20 years of advances and challenges and drawing on data from public research and evidence-based practices. For more ...
Source: NIDCR Science News - March 3, 2022 Category: Dentistry Source Type: news
Development and validation of a tool for evaluating YouTube-based medical videos
ConclusionCollectively, our findings indicated that the MQ-VET is a valid and reliable tool that will help to standardize future evaluations of online medical videos.
Source: Irish Journal of Medical Science - November 25, 2021 Category: General Medicine Source Type: research
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
M024 don ’t stop hpv vaccine with one dose left, go see an allergist!
HPV is the most common sexually transmitted infection in the US. HPV is associated with cervical, vulvar, and vaginal cancer in females, penile cancer in males, and anal and oropharyngeal cancer in both females and males. FDA-approved in 2014, human papillomavirus vaccine (9vHPV, Merck), aids in the prevention of diseases caused by nine types of HPV. 9vHPV is now licensed in the US for females and males ages 9 through 45 years. For those 15 years and older, a 3-dose schedule is recommended.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: M. Lukas, M. Tankersley Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
CDC Authorizes Boosters of Moderna and Johnson & Johnson COVID-19 Vaccines
Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), authorized booster doses of COVID-19 vaccines for certain groups. Walensky followed the advice of a CDC expert panel, which recommended the boosters in in two unanimous votes earlier in the day.
The 15-member Advisory Committee on Immunization Practices (ACIP) advised that anyone who was initially vaccinated with the Moderna shot get a booster at least six months later, and that J&J-Janssen recipients receive a booster at least two months after their initial vaccination. The endorsement follows a similar decision from the Food and ...
Source: TIME: Health - October 21, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
CDC Authorizes Boosters of Moderna and Johnson & Johnson COVID-19 Vaccines
Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), authorized booster doses of COVID-19 vaccines for certain groups. Walensky followed the advice of a CDC expert panel, which recommended the boosters in in two unanimous votes earlier in the day.
The 15-member Advisory Committee on Immunization Practices (ACIP) advised that anyone who was initially vaccinated with the Moderna shot get a booster at least six months later, and that J&J-Janssen recipients receive a booster at least two months after their initial vaccination. The endorsement follows a similar decision from the Food and ...
Source: TIME: Health - October 21, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Designing of DNA Vaccine Based on a Secretory Form of Major Capsid Protein of Human Papillomavirus Type 18
In conclusion, pVAX1-tPA-PADRE-L1 recombinant plasmid is a highly immunogenic construct and suggests as a promising candidate for vaccine development against HPV type 18 in low-middle-income countries.PMID:34664812 | DOI:10.18502/ijaai.v20i5.7403
Source: Iranian Journal of Allergy, Asthma and Immunology - October 19, 2021 Category: Allergy & Immunology Authors: Somayeh Shokri Shahab Mahmoudvand Manoochehr Makvandi Reza Taherkhani Mohammad Rashno Farid Azizi Jalilian Kambiz Ahmadi Angali Mohammad Ali Foroughi Source Type: research
